Trial · NCT06206512
Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
NCT06206512, Phase 2, Completed, Sarfez Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder. Trials, record NCT06206512. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06206512
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
- NCT number
- NCT06206512
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 24 participants, actual
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Conditions
- Heart Failure, Overactive Bladder, Incontinence
- Interventions
- Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo
- First posted
- 2024-01-16
- Last updated
- 2026-03-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Health-Related Quality of Life (HRQoL) Treatment Effect | After enrollment to the end of treatment at 8 weeks | Within-subject difference in change from baseline in HRQoL total score between extended-release torsemide (ERT) and immediate-release torsemide (IRT) treatment periods. Clinical significance interpreted using a Patient Global Impression of Change (PGI-C)-anchored minimum clinically important difference (MCID). |
| Secondary | Voiding, Urgency, and Urgency-Incontinence Episodes (24-hour) | After enrollment to the end of treatment at 8 weeks | Within-subject difference in mean daily episodes of voiding, urgency, and urgency-incontinence within 24 hours after dosing between ERT and IRT periods. |
| Secondary | Voiding, Urgency, and Urgency-Incontinence Episodes (8-hour) | After enrollment to the end of treatment at 8 weeks | Within-subject difference in mean daily episodes of voiding, urgency, and urgency-incontinence within 8 hours after dosing between ERT and IRT periods. |
| Secondary | Bladder Symptom Assessment (BSA) Score | After enrollment to the end of treatment at 8 weeks | Change from baseline in BSA total score between ERT and IRT periods. |
| Secondary | Health-Related Quality of Life (HRQoL) Responder Proportion | After enrollment to the end of treatment at 8 weeks | Proportion of participants achieving clinically meaningful improvement in HRQoL (defined by PGI-C-anchored MCID), compared between ERT and IRT periods. |
| Secondary | Patient Global Impression of Change (PGI-C) | After enrollment to the end of treatment at 8 weeks | Within-subject comparison of PGI-C ratings between ERT and IRT across domains including frequency, urgency, urgency-incontinence, overall bladder problems, daily life, and treatment satisfaction. |
| Secondary | Six-Minute Walk Distance (6MWD) | After enrollment to the end of treatment at 8 weeks | Change from baseline in 6MWD between ERT and IRT periods. |
| Secondary | NT-proBNP | From enrollment to the end of treatment at 8 weeks | Change from baseline in NT-proBNP levels between ERT and IRT periods. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06206512
GET https://conductscience.org/api/trials/v1/NCT06206512/registered